Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20799921 | 1.00 | PRMT6 (0.35) | PRMT6RIPK1METAP2MEN1EPHX2 | |
| SCHEMBL14868708 | 0.84 | RIPK1 (0.46) | PRMT6RIPK1KMT2A | |
| SCHEMBL14868714 | 0.83 | PRMT6 (0.42) | PRMT6METAP2MEN1EPHX2KMT2A | |
| SCHEMBL14868627 | 0.80 | PRMT6 (0.53) | PRMT6METAP2MEN1EPHX2KMT2A | |
| SCHEMBL14868841 | 0.78 | PRMT6 (0.37) | PRMT6RIPK1METAP2MEN1EPHX2 | |
| SCHEMBL14868752 | 0.77 | PRMT6 (0.39) | PRMT6RIPK1 | |
| SCHEMBL14868736 | 0.75 | PRMT6 (0.46) | PRMT6RIPK1METAP2MEN1EPHX2 | |
| SCHEMBL24433735 | 0.74 | RIPK1 (0.36) | PRMT6RIPK1 | |
| SCHEMBL19165093 | 0.73 | CHRM2 (0.32) | — | |
| SCHEMBL19164710 | 0.72 | PRMT6 (0.40) | PRMT6RIPK1METAP2MEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | PRMT6 1349/4885RIPK1 3097/4885METAP2 837/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | PRMT6 1349/4885RIPK1 3097/4885METAP2 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.